U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Hawaii Health Systems Corporation dba Kona Community Hospital Pharmacy - 611130 - 06/27/2022
  1. Warning Letters

CLOSEOUT LETTER

Hawaii Health Systems Corporation dba Kona Community Hospital Pharmacy MARCS-CMS 611130 —

Delivery Method:
Via Email Delivery Confirmation
Product:
Drugs
Recipient:
Recipient Name
Clayton McGhan, MHA
Recipient Title
Interim West Hawaii Regional CEO
Hawaii Health Systems Corporation dba Kona Community Hospital Pharmacy

79-1019 Kaukapila Street
Kealakekua, HI 96750
United States

Issuing Office:
Division of Pharmaceutical Quality Operations IV

United States

Dear Mr. McGhan:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter WL #611130 dated February 23, 2021. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
CDR Steven E. Porter, Jr.
Director, Division of Pharmaceutical Quality Operations IV

Back to Top